Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2670)
All Articles published online
|
Feb 28, 2005 (publication date) through Apr 25, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Urcelay E, Mendoza JL, Martínez A, Fernández L, Taxonera C, Díaz-Rubio M, de la Concha EG. IBD5 polymorphisms in inflammatory bowel disease: Association with response to infliximab. World J Gastroenterol 2005; 11(8): 1187-1192 [PMID: 15754402 DOI: 10.3748/wjg.v11.i8.1187] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v11/i8/1187.htm |
| Number | Citing Articles |
| 1 |
ATP-binding cassette transporter ABCG2 (BCRP) and ABCB1 (MDR1) variants are not associated with disease susceptibility, disease phenotype response to medical therapy or need for surgeryin Hungarian patients with inflammatory bowel diseases. Scandinavian Journal of Gastroenterology 2007; 42(6): 726 doi: 10.1080/00365520601101559
|
| 2 |
Lilla Lakner, Veronika Csöngei, Patrícia Sarlós, Luca Járomi, Enikő Sáfrány, Márta Varga, Péter Orosz, Lili Magyari, Judit Bene, Pál Miheller, Zsolt Tulassay, Béla Melegh. IGR2096a_1 T and IGR2198a_1 C alleles on IBD5 locus of chromosome 5q31 region confer risk for Crohn’s disease in Hungarian patients. International Journal of Colorectal Disease 2009; 24(5): 503 doi: 10.1007/s00384-009-0670-x
|
| 3 |
Jonathan L. Digby-Bell, Raja Atreya, Giovanni Monteleone, Nick Powell. Interrogating host immunity to predict treatment response in inflammatory bowel disease. Nature Reviews Gastroenterology & Hepatology 2020; 17(1): 9 doi: 10.1038/s41575-019-0228-5
|
| 4 |
Sophie Vieujean, Edouard Louis. Precision medicine and drug optimization in adult inflammatory bowel disease patients. Therapeutic Advances in Gastroenterology 2023; 16: 175628482311733 doi: 10.1177/17562848231173331
|
| 5 |
Wouter M. Kooloos, Dirk J. de Jong, Tom W.J. Huizinga, Henk-Jan Guchelaar. Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease. Drug Discovery Today 2007; 12(3-4): 125 doi: 10.1016/j.drudis.2006.11.013
|
| 6 |
Corey A. Siegel, Gil Y. Melmed. Review: Predicting response to anti-TNF agents for the treatment of Crohn's disease. Therapeutic Advances in Gastroenterology 2009; 2(4): 245 doi: 10.1177/1756283X09336364
|
| 7 |
Ashwin N. Ananthakrishnan, Ramnik J. Xavier. How Does Genotype Influence Disease Phenotype in Inflammatory Bowel Disease?. Inflammatory Bowel Diseases 2013; : 1 doi: 10.1097/MIB.0b013e318281f5c5
|
| 8 |
Ulrich Klotz, Alexander Teml, Matthias Schwab. Clinical Pharmacokinetics and Use??of??Infliximab. Clinical Pharmacokinetics 2007; 46(8): 645 doi: 10.2165/00003088-200746080-00002
|
| 9 |
Marla C. Dubinsky, Ling Mei, Madison Friedman, Tanvi Dhere, Talin Haritunians, Hakon Hakonarson, Cecilia Kim, Joseph Glessner, Stephan R. Targan, Dermot P. McGovern, Kent D. Taylor, Jerome I. Rotter. Genome wide association (GWA) predictors of anti-TNFα therapeutic responsiveness in pediatric inflammatory bowel disease. Inflammatory Bowel Diseases 2010; 16(8): 1357 doi: 10.1002/ibd.21174
|
| 10 |
Karen van Hoeve, Ilse Hoffman, Severine Vermeire. Therapeutic drug monitoring of anti-TNF therapy in children with inflammatory bowel disease. Expert Opinion on Drug Safety 2018; 17(2): 185 doi: 10.1080/14740338.2018.1413090
|
| 11 |
Johan Van Limbergen, Richard K. Russell, Elaine R. Nimmo, Jack Satsangi. The Genetics of Inflammatory Bowel Disease. The American Journal of Gastroenterology 2007; 102(12): 2820 doi: 10.1111/j.1572-0241.2007.01527.x
|
| 12 |
Mahmoud H Mosli, William J Sandborn, Richard B Kim, Reena Khanna, Bandar Al-Judaibi, Brian G Feagan. Toward a Personalized Medicine Approach to the Management of Inflammatory Bowel Disease. American Journal of Gastroenterology 2014; 109(7): 994 doi: 10.1038/ajg.2014.110
|
| 13 |
Vinciane Dideberg, Emilie Théâtre, Frédéric Farnir, Séverine Vermeire, Paul Rutgeerts, Martine De Vos, Jacques Belaiche, Denis Franchimont, André Van Gossum, Edouard Louis, Vincent Bours. The TNF/ADAM 17 system: implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohn's disease. Pharmacogenetics and Genomics 2006; 16(10): 727 doi: 10.1097/01.fpc.0000230117.26581.a4
|
| 14 |
Ad A. van Bodegraven, Cisca Wijmenga. Essentials of Genomic and Personalized Medicine. 2010; : 575 doi: 10.1016/B978-0-12-374934-5.00045-3
|
| 15 |
Vinciane Dideberg, E. Louis, V. Bours. Pharmacogénétique de l’infliximab dans la maladie de Crohn. Acta Endoscopica 2007; 37(4): 521 doi: 10.1007/BF02961799
|
| 16 |
Jimmy K Limdi, Katherine A Siminovitch, William Newman. Genetic dissection of inflammatory bowel disease: unravelling etiology and improving diagnostics. Expert Review of Clinical Immunology 2005; 1(4): 609 doi: 10.1586/1744666X.1.4.609
|
| 17 |
Melissa A Smith, Anthony M Marinaki, Jeremy D Sanderson. Pharmacogenomics in the treatment of inflammatory bowel disease. Pharmacogenomics 2010; 11(3): 421 doi: 10.2217/pgs.10.4
|
| 18 |
B. Weiss, O. Lebowitz, H. H. Fidder, I. Maza, A. Levine, R. Shaoul, S. Reif, Y. Bujanover, A. Karban. Response to Medical Treatment in Patients with Crohn’s Disease: The Role of NOD2/CRAD15, Disease Phenotype, and Age of Diagnosis. Digestive Diseases and Sciences 2010; 55(6): 1674 doi: 10.1007/s10620-009-0936-8
|
| 19 |
Loris Lopetuso, Viviana Gerardi, Valerio Papa, Franco Scaldaferri, Gian Rapaccini, Antonio Gasbarrini, Alfredo Papa. Can We Predict the Efficacy of Anti-TNF-α Agents?. International Journal of Molecular Sciences 2017; 18(9): 1973 doi: 10.3390/ijms18091973
|
| 20 |
Irene Marafini, Giovanni Monteleone. Precision Medicine in Inflammatory Bowel Diseases. Frontiers in Pharmacology 2021; 12 doi: 10.3389/fphar.2021.653924
|
| 21 |
Kristin E Burke, Hamed Khalili, John J Garber, Talin Haritunians, Dermot P B McGovern, Ramnik J Xavier, Ashwin N Ananthakrishnan. Genetic Markers Predict Primary Nonresponse and Durable Response to Anti–Tumor Necrosis Factor Therapy in Ulcerative Colitis. Inflammatory Bowel Diseases 2018; 24(8): 1840 doi: 10.1093/ibd/izy083
|
| 22 |
Michael Camilleri. The role of pharmacogenetics in nonmalignant gastrointestinal diseases. Nature Reviews Gastroenterology & Hepatology 2012; 9(3): 173 doi: 10.1038/nrgastro.2012.2
|
| 23 |
Ad A. van Bodegraven, Cisca Wijmenga. Genomic and Personalized Medicine. 2009; : 1040 doi: 10.1016/B978-0-12-369420-1.00086-X
|
| 24 |
Boris Gole, Uroš Potočnik. Pre-Treatment Biomarkers of Anti-Tumour Necrosis Factor Therapy Response in Crohn’s Disease—A Systematic Review and Gene Ontology Analysis. Cells 2019; 8(6): 515 doi: 10.3390/cells8060515
|
| 25 |
Eleanora Anna Margaretha Festen, Cisca Wijmenga, Rinse K Weersma. Genomic and Personalized Medicine. 2013; : 863 doi: 10.1016/B978-0-12-382227-7.00073-2
|
| 26 |
Uri Netz, Jane Victoria Carter, Maurice Robert Eichenberger, Gerald Wayne Dryden, Jianmin Pan, Shesh Nath Rai, Susan Galandiuk. Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn’s disease. World Journal of Gastroenterology 2017; 23(27): 4958-4967 doi: 10.3748/wjg.v23.i27.4958
|
| 27 |
Javier P Gisbert, María Chaparro. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice. Journal of Crohn's and Colitis 2020; 14(5): 694 doi: 10.1093/ecco-jcc/jjz195
|
| 28 |
Vito Annese, Monica Annese. Precision Medicine in Inflammatory Bowel Disease. Diagnostics 2023; 13(17): 2797 doi: 10.3390/diagnostics13172797
|
| 29 |
Alexander Teml, Susanne Karner, Elke Schaeffeler, Matthias Schwab. Pharmacogenetics and Individualized Therapy. 2012; : 323 doi: 10.1002/9781118116494.ch11
|
| 30 |
Ryan Ungaro, Judy Cho. Biomarkers in Inflammatory Bowel Diseases. 2019; : 333 doi: 10.1007/978-3-030-11446-6_28
|
| 31 |
Clara Caenepeel, Nasim Sadat Seyed Tabib, Sara Vieira‐Silva, Séverine Vermeire. Review article: how the intestinal microbiota may reflect disease activity and influence therapeutic outcome in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 2020; 52(9): 1453 doi: 10.1111/apt.16096
|
| 32 |
Konstantinos Papamichael, Ann Gils, Paul Rutgeerts, Barrett G. Levesque, Séverine Vermeire, William J. Sandborn, Niels Vande Casteele. Role for Therapeutic Drug Monitoring During Induction Therapy with TNF Antagonists in IBD. Inflammatory Bowel Diseases 2015; 21(1): 182 doi: 10.1097/MIB.0000000000000202
|
| 33 |
Philippe Goyette, Catherine Labbé, Truc T. Trinh, Ramnik J. Xavier, John D. Rioux. Molecular pathogenesis of inflammatory bowel disease: Genotypes, phenotypes and personalized medicine. Annals of Medicine 2007; 39(3): 177 doi: 10.1080/07853890701197615
|
| 34 |
Grant E Barber, Vijay Yajnik, Hamed Khalili, Cosmas Giallourakis, John Garber, Ramnik Xavier, Ashwin N Ananthakrishnan. Genetic Markers Predict Primary Non-Response and Durable Response To Anti-TNF Biologic Therapies in Crohn’s Disease. American Journal of Gastroenterology 2016; 111(12): 1816 doi: 10.1038/ajg.2016.408
|
| 35 |
Robert D Little, Thisun Jayawardana, Sabrina Koentgen, Fan Zhang, Susan J Connor, Alex Boussioutas, Mark G Ward, Peter R Gibson, Miles P Sparrow, Georgina L Hold. Pathogenesis and precision medicine for predicting response in inflammatory bowel disease: advances and future directions. eGastroenterology 2024; 2(1): e100006 doi: 10.1136/egastro-2023-100006
|
| 36 |
Katja Repnik, Uroš Potočnik. Haplotype in the IBD5 region is associated with refractory Crohn’s disease in Slovenian patients and modulates expression of the SLC22A5 gene. Journal of Gastroenterology 2011; 46(9): 1081 doi: 10.1007/s00535-011-0426-6
|
| 37 |
Raja Atreya, Markus F. Neurath, Britta Siegmund. Personalizing Treatment in IBD: Hype or Reality in 2020? Can We Predict Response to Anti-TNF?. Frontiers in Medicine 2020; 7 doi: 10.3389/fmed.2020.00517
|
| 38 |
Mathurin Flamant, Xavier Roblin. Inflammatory bowel disease: towards a personalized medicine. Therapeutic Advances in Gastroenterology 2018; 11: 1756283X1774502 doi: 10.1177/1756283X17745029
|
| 39 |
Vinciane Dideberg, Edouard Louis, Frédéric Farnir, Sabrina Bertoli, Séverine Vermeire, Paul Rutgeerts, Martine De Vos, André Van Gossum, Jacques Belaiche, Vincent Bours. Lymphotoxin alpha gene in Crohn's disease patients: absence of implication in the response to infliximab in a large cohort study. Pharmacogenetics and Genomics 2006; 16(5): 369 doi: 10.1097/01.fpc.0000204993.91806.b1
|
| 40 |
Leif Törkvist, Colin L. Noble, Mikael Lördal, Urban Sjöqvist, Ulrik Lindforss, Elaine R. Nimmo, Robert Löfberg, Richard K. Russell, Jack Satsangi. Contribution of the IBD5 locus to Crohn's disease in the Swedish population. Scandinavian Journal of Gastroenterology 2007; 42(2): 200 doi: 10.1080/00365520600842278
|
| 41 |
Rita Prajapati, Darren Plant, Anne Barton. Genetic and genomic predictors of anti-TNF response. Pharmacogenomics 2011; 12(11): 1571 doi: 10.2217/pgs.11.114
|
| 42 |
Alfonso Martínez, Maria del Carmen Martín, Juan L Mendoza, Carlos Taxonera, Manuel Díaz-Rubio, Emilio G de la Concha, Elena Urcelay. Association of the organic cation transporter OCTN genes with Crohn's disease in the Spanish population. European Journal of Human Genetics 2006; 14(2): 222 doi: 10.1038/sj.ejhg.5201529
|
| 43 |
Ashwin N Ananthakrishnan. Personalizing therapy for inflammatory bowel diseases. Expert Review of Gastroenterology & Hepatology 2013; 7(6): 549 doi: 10.1586/17474124.2013.824693
|
| 44 |
N. S. Ding, A. Hart, P. De Cruz. Systematic review: predicting and optimising response to anti‐TNF therapy in Crohn's disease – algorithm for practical management. Alimentary Pharmacology & Therapeutics 2016; 43(1): 30 doi: 10.1111/apt.13445
|
| 45 |
K. R. HERRLINGER, D. P. JEWELL. Review article: interactions between genotype and response to therapy in inflammatory bowel diseases. Alimentary Pharmacology & Therapeutics 2006; 24(10): 1403 doi: 10.1111/j.1365-2036.2006.03147.x
|
| 46 |
Soo Kyung Park, Yea Bean Kim, Sangsoo Kim, Chil Woo Lee, Chang Hwan Choi, Sang-Bum Kang, Tae Oh Kim, Ki Bae Bang, Jaeyoung Chun, Jae Myung Cha, Jong Pil Im, Min Suk Kim, Kwang Sung Ahn, Seon-Young Kim, Dong Il Park. Development of a Machine Learning Model to Predict Non-Durable Response to Anti-TNF Therapy in Crohn’s Disease Using Transcriptome Imputed from Genotypes. Journal of Personalized Medicine 2022; 12(6): 947 doi: 10.3390/jpm12060947
|
| 47 |
Michael J. Murphy, Carlo Pincelli, Diane M. Hoss, Riccardo G. Borroni. Molecular Diagnostics in Dermatology and Dermatopathology. 2011; : 419 doi: 10.1007/978-1-60761-171-4_21
|
| 48 |
Cecile Krejsa, Mark Rogge, Wolfgang Sadee. Protein therapeutics: new applications for pharmacogenetics. Nature Reviews Drug Discovery 2006; 5(6): 507 doi: 10.1038/nrd2039
|
| 49 |
Seiya Nakahara, Yoshiaki Arimura, Katsuhiko Saito, Akira Goto, Satoshi Motoya, Yasuhisa Shinomura, Atsushi Miyamoto, Kohzoh Imai. Association of SLC22A4/5 Polymorphisms with Steroid Responsiveness of Inflammatory Bowel Disease in Japan. Diseases of the Colon & Rectum 2008; 51(5): 598 doi: 10.1007/s10350-008-9208-5
|
| 50 |
Lili Magyari, Judit Bene, Katalin Komlósi, Gábor Talián, Bernadett Faragó, Veronika Csöngei, Luca Járomi, Enikő Sáfrány, Csilla Sipeky, Lilla Lakner, Márta Varga, Beáta Gasztonyi, Béla Melegh. Prevalence of SLC22A4 1672T and SLC22A5 −207C combination defined TC haplotype in Hungarian ulcerative colitis patients. Pathology & Oncology Research 2007; 13(1): 53 doi: 10.1007/BF02893441
|
| 51 |
Jason Reinglas, Lorant Gonczi, Zsuzsanna Kurt, Talat Bessissow, Peter L Lakatos. Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases. World Journal of Gastroenterology 2018; 24(32): 3567-3582 doi: 10.3748/wjg.v24.i32.3567
|
| 52 |
Michael Economou, Georgios Pappas. New global map of Crohnʼs disease: Genetic, environmental, and socioeconomic correlations. Inflammatory Bowel Diseases 2008; 14(5): 709 doi: 10.1002/ibd.20352
|
| 53 |
Carlo Pincelli, Marco Pignatti, Riccardo G. Borroni. Pharmacogenomics in dermatology: from susceptibility genes to personalized therapy. Experimental Dermatology 2009; 18(4): 337 doi: 10.1111/j.1600-0625.2009.00852.x
|
| 54 |
Uri Kopylov, Ernest Seidman. Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease. Therapeutic Advances in Gastroenterology 2016; 9(4): 513 doi: 10.1177/1756283X16638833
|
| 55 |
Claudia Reinhard, John D. Rioux. Role of the IBD5 susceptibility locus in the inflammatory bowel diseases. Inflammatory Bowel Diseases 2006; 12(3): 227 doi: 10.1097/01.MIB.0000202413.16360.a1
|
| 56 |
Anna Latiano, O. Palmieri, Rossella M. Valvano, Renata D'Inca, Maurizio Vecchi, Angelo Ferraris, Giacomo C. Sturniolo, Luisa Spina, Giovanni Lombardi, Bruno Dallapiccola, Angelo Andriulli, Marcella Devoto, Vito Annese. Contribution of IBD5 Locus to Clinical Features of IBD Patients. The American Journal of Gastroenterology 2006; 101(2): 318 doi: 10.1111/j.1572-0241.2006.00389.x
|
| 57 |
Rebecca L Roberts, Murray L Barclay. Current relevance of pharmacogenetics in immunomodulation treatment for Crohn's disease. Journal of Gastroenterology and Hepatology 2012; 27(10): 1546 doi: 10.1111/j.1440-1746.2012.07220.x
|
| 58 |
Johan Van Limbergen, Richard K. Russell, Elaine R. Nimmo, Gwo-Tzer Ho, Ian D. Arnott, David C. Wilson, Jack Satsangi. Genetics of the innate immune response in inflammatory bowel disease. Inflammatory Bowel Diseases 2007; 13(3): 338 doi: 10.1002/ibd.20096
|
| 59 |
Gonzalo Jesús Gómez-Gómez, Ángeles Masedo, Carmen Yela, Maria del Pilar Martínez-Montiel, Begoña Casís. Current stage in inflammatory bowel disease: What is next?. World Journal of Gastroenterology 2015; 21(40): 11282-11303 doi: 10.3748/wjg.v21.i40.11282
|